Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003736 · ClinicalTrials.gov registry record · NA
MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
NCT00003736 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 200 participants.
The verdict
NCT00003736, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
Study Summary
RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for breast cancer. Diagnostic procedures such as MRI may improve the ability to detect breast cancer. PURPOSE: Screening and diagnostic trial to study the effectiveness of MRI scans in women who are at high risk for developing breast cancer.
Interventions
- PROCEDURE biopsy
- DRUG motexafin gadolinium
- PROCEDURE magnetic resonance imaging
- PROCEDURE breast imaging study
- PROCEDURE comparison of screening methods
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 1999-06 |
| Est. Completion | 2002-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003736
The ClinicalTrials.gov registry entry for NCT00003736 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which biopsy is the first listed.
NCT00003736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003736 about?
NCT00003736 is a clinical study titled "MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer". RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for breast cancer. Diagnostic procedures such as MRI may improve the ability to detect breast cancer. PURPOSE: Screening and diagnostic trial to study the effectiveness of MRI scans in women who ...
What is the current status of trial NCT00003736?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 1999-06. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00003736?
The interventions under investigation include: biopsy (PROCEDURE), motexafin gadolinium (DRUG), magnetic resonance imaging (PROCEDURE), breast imaging study (PROCEDURE), comparison of screening methods (PROCEDURE).
Who is sponsoring clinical trial NCT00003736?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.